$8.62
4.54%
Nasdaq, Fri, Nov 15 2024
ISIN
US4884451075
Symbol
KMPH
Sector
Industry

KemPharm, Inc. Stock price

$8.62
+0.24 2.86% 1M
+3.80 78.84% 6M
+2.07 31.60% YTD
+4.39 103.78% 1Y
-0.55 6.00% 3Y
+0.14 1.65% 5Y
-170.58 95.19% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.41 4.54%
ISIN
US4884451075
Symbol
KMPH
Sector
Industry

Key metrics

Market capitalization $453.57m
Enterprise Value $459.46m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 18.53
P/S ratio (TTM) P/S ratio 18.30
P/B ratio (TTM) P/B ratio 6.58
Revenue growth (TTM) Revenue growth 49.65%
Revenue (TTM) Revenue $24.79m
EBIT (operating result TTM) EBIT $-86.26m
Free Cash Flow (TTM) Free Cash Flow $-69.65m
Cash position $89.38m
EPS (TTM) EPS $-1.97
P/E forward negative
P/S forward 23.59
EV/Sales forward 22.13
Short interest 4.23%
Show more

Is KemPharm, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

KemPharm, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a KemPharm, Inc. forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a KemPharm, Inc. forecast:

Buy
100%

Financial data from KemPharm, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
25 25
50% 50%
100%
- Direct Costs 18 18
1,030% 1,030%
73%
6.59 6.59
56% 56%
27%
- Selling and Administrative Expenses 48 48
98% 98%
193%
- Research and Development Expense 39 39
15% 15%
159%
-81 -81
85% 85%
-326%
- Depreciation and Amortization 5.53 5.53
963% 963%
22%
EBIT (Operating Income) EBIT -86 -86
95% 95%
-348%
Net Profit -85 -85
113% 113%
-343%

In millions USD.

Don't miss a Thing! We will send you all news about KemPharm, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.

Head office United States
CEO Neil McFarlane
Employees 69
Founded 2006
Website zevra.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today